Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E6) - Biotin
Product Code:
LEI-LT7091
LEI-LT7091
Host Type:
Virus
Virus
Antibody Isotype:
Human IgG1
Human IgG1
Antibody Clonality:
Monoclonal
Monoclonal
Antibody Clone:
NP1-E6
NP1-E6
Regulatory Status:
RUO
RUO
Target Species:
- SARS-CoV-2
- Virus
Application:
Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Blue Ice
Blue Ice
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
No additional charges, what you see is what you pay! *
Code | Size | Price |
---|
LEI-LT7091-50ug | 50 ug | £377.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
- Further Information
- References
- Related Products
- Show All
Further Information
Antigen Distribution:
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
SARS-CoV-2 Nucleocapsid (N) Protein
Long Description:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARS-CoV-2 shares 79.6% identity with the original SARS-CoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein9. Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.
NCBI Gene:
43740575
Target:
SARS-CoV-2 Nucleocapsid (N)
References
1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270?273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265?269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
8. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
9. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Related Products
Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Spike RBD (Clone: 2165) | LEI-LT1900 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-SARS-CoV-2 Spike NTD (Clone 2146) | LEI-LT2000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV-2 Spike RBD (Clone: 2838) | LEI-LT3000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV-2 Spike RBD (Clone: 2381) | LEI-LT4000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV-2 Spike RBD (Clone: 2355) | LEI-LT5000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-SARS-CoV-2 Spike NTD (Clone 2215) | LEI-LT6000 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant SARS-CoV-2, Nucleocapsid (N) Protein | LEI-S854 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||